Skip to content

Study · Non-randomized trial · n = 21 · 2008

4 results

Pegvisomant-primed GH stimulation test.

Radetti G, Wu Z, Elsedfy HH, El Kholy M, Bozzola M, Strasburger CJ

Clinical endocrinology19 Nov 2007Cited by 3 (Europe PMC)

PMID18031320 (opens in a new tab)DOI10.1111/j.1365-2265.2007.03132.x (opens in a new tab)PepBankPUB-18031320
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In short children, pegvisomant priming decreased IGF-I SDS from -1.75 to -2.65 (P < 0.0001).

    In plain wordsIn short children, IGF-I scores fell after pegvisomant priming compared with before priming.

    Peptide
    Pegvisomant
    Outcome
    DecreaseIGF-I SDS after priming
    Study

    n = 21

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    IGF-I SDS
    −1.75 SDS
    before priming
    IGF-I SDS
    −2.65 SDS
    after priming

    Source sentences

    Summary
    There was a significant decrease of IGF-I SDS following pegvisomant (-1.75 +/- 0.24 vs.-2.65 +/- 0.23; P < 0.0001) and a significant increase of the GH-peak (6.2 +/- 0.91 vs. 15.3 +/- 2.30 microg/l; P < 0.0001).
    2 context sentences
    Summary · context
    Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of < 2 SD scores below the mean were included in the study.
    Summary · context
    At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an L-DOPA stimulation test was repeated.
  2. 02HumanNon-randomized trialActivity measurement

    In short children, pegvisomant priming increased the GH peak from 6.2 to 15.3 microg/l (P < 0.0001).

    In plain wordsIn short children, the growth hormone peak rose after pegvisomant priming compared with before priming.

    Peptide
    Pegvisomant
    Outcome
    IncreaseGH peak after priming
    Study

    n = 21

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    GH peak
    6.2 microg/l
    before priming
    GH peak
    15.3 microg/l
    after priming

    Source sentences

    Summary
    There was a significant decrease of IGF-I SDS following pegvisomant (-1.75 +/- 0.24 vs.-2.65 +/- 0.23; P < 0.0001) and a significant increase of the GH-peak (6.2 +/- 0.91 vs. 15.3 +/- 2.30 microg/l; P < 0.0001).
    2 context sentences
    Summary · context
    Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of < 2 SD scores below the mean were included in the study.
    Summary · context
    At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an L-DOPA stimulation test was repeated.
  3. 03HumanNon-randomized trialActivity measurement

    Among short children with initially insufficient GH responses, 10 (55.5%) showed normal secretion after pegvisomant priming.

    In plain wordsAmong short children with initially low growth hormone responses, 10 showed normal secretion after pegvisomant priming.

    Peptide
    Pegvisomant
    Outcome
    IncreaseNormal secretion after priming
    Study

    n = 18

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    Normal secretion
    10 children
    reported result
    Normal secretion
    55.5%
    reported result

    Source sentences

    Summary
    Ten of them (55.5%) showed normal secretion after priming with pegvisomant, while insufficient secretory reserve was confirmed in the remaining eight.
    3 context sentences
    Summary · context
    Among the 21 patients examined, 18 (85.7%) had an insufficient response (< 10 microg/l) at the first stimulation.
    Summary · context
    Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of < 2 SD scores below the mean were included in the study.
    Summary · context
    At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an L-DOPA stimulation test was repeated.
  4. 04HumanNon-randomized trialActivity measurement

    Among short children with initially insufficient GH responses, eight retained insufficient secretory reserve after pegvisomant priming.

    In plain wordsAmong short children with initially low growth hormone responses, eight still had low responses after pegvisomant priming.

    Peptide
    Pegvisomant
    Outcome
    Not applicablePersistently insufficient reserve
    Study

    n = 18

    Comparator
    Before pegvisomant priming
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 mg/kg · subcutaneousAs given in this study (human).

    Measurements

    Insufficient reserve
    8 children
    reported result

    Source sentences

    Summary
    Ten of them (55.5%) showed normal secretion after priming with pegvisomant, while insufficient secretory reserve was confirmed in the remaining eight.
    3 context sentences
    Summary · context
    Among the 21 patients examined, 18 (85.7%) had an insufficient response (< 10 microg/l) at the first stimulation.
    Summary · context
    Twenty-one short children (8 males and 13 females), aged 1.0-14.5 years, with a height of < 2 SD scores below the mean were included in the study.
    Summary · context
    At the end of the test, 1 mg/kg of pegvisomant was given subcutaneously and 3 days later an L-DOPA stimulation test was repeated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT01804413

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Oregon Health and Science Universityn = 10Mar 2011 to est. Dec 2013

Adults Growth Hormone Deficiency.

Trial pageClinicalTrials.govUpdated 24 Oct 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.